“Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis”, FE, vol. 23, no. 1, Nov. 2022, doi: 10.7175/fe.v23i1.1532.